Background/Aims
Introduction
Currently intraocular pressure (IOP) is the only modifiable risk factor in patients with glaucoma and several studies have demonstrated reduced visual field progression when IOP has been lowered. [1] [2] [3] Glaucoma patients with advanced visual field loss represent a difficult group to manage as presentation with advanced visual field loss is a risk factor for further progression and blindness and therefore a very low IOP may be required to avoid further visual field loss. [1] [2] [3] [4] [5] The use of Mitomycin C (MMC) in trabeculectomy surgery has been shown to reduce the risk of failure in certain groups. [6] In addition the success of modern glaucoma surgery has been further enhanced by the use of postoperative bleb manipulation. [7] [8] [9] The safety of modern glaucoma surgery using intraoperative techniques such as tight closure of the scleral flap and the anterior chamber maintainer to reduce the risk of hypotony have been encapsulated in the concept of the safe trabeculectomy. [10, 11] In this study we assess outcome of trabeculectomy surgery combined with MMC in patients with advanced glaucoma to document success in terms of IOP and visual outcomes. In addition we quantify the post-operative interventions undertaken to achieve these outcomes.
Methods
All trabeculectomies and phaco-trabeculectomies carried out by a single surgical team between October 2000 and July 2008 were reviewed. Data on all trabeculetomies was entered into a surgical database at the time of surgery and updated at each follow-up visit. Patients who had severe pre-operative glaucomatous visual field defects, defined as an MD greater than 20dB and patients who had poor acuity secondary to glaucoma which precluded formal visual field assessment were identified. Demographic and clinical information including any post-operative interventions was available from the database. All identified cases were included with no specific exclusion criteria. Data on all patients were included until the last recorded appointment which was considered the end of their follow-up.
An intervention was defined as any procedure or process undertaken after trabeculectomy surgery aimed at enhancing the success of the surgical outcome.
These were bleb massage, suture removal, 5-fluorourcil (5-FU) injection and needling in combination with 5-FU injection. Bleb massage was performed by applying digital pressure to the globe through the upper eyelid behind the posterior lip of the scleral flap.
Statistical analysis was undertaken using SPSS V.14.0. The tests for statistically significant differences between variables were performed using the 2 were taken to indicate significance.
The success of surgical outcome was defined as unqualified when no additional medication was required or qualified when additional medication was required to achieve the specific IOP definition. Success was also defined at two IOP cut-off points (IOP <21 mm Hg and IOP <16 mm Hg). Furthermore sustained hypotony <6mmHg for greater than 6 months was considered a failure. Visual acuity was measured on a Snellen chart and a reduction of 2 or more lines was considered significant.
The safe trabeculectomy approach was used. [11] The dosage and exposure time of MMC was varied for patients according to the various preoperative and peroperative risk factors for surgical failure. The final dosage decision was taken once scleral exposure had been achieved. The dosage of MMC was defined as the product of the MMC concentration and the application time.
Results
In total 103 eyes were identified for the study ( The majority of patients achieved a successful outcome, although 35 (33.7%) required drops at the end of their follow-up to achieve the target IOP (mean number of drops 2.2, SD 1.08, range 1-4). This represented a significant reduction in the number of drops required. When viewing the group as a whole a mean number of 0.74 drops per-patient were required compared to an average of 2.8 pre-operatively (figure 1).
There was a reduction in the number of patients achieving an unqualified success year on year, declining from 82% and 88% (<16mmHg and <21mmHg
respectively) at year 1 (n=88) to 52% and 56% at year 5 (n=27). However, there was no real reduction in qualified success numbers which remained relatively static at roughly 85% and 95% for the duration (for IOPs <16mmHg and <21mmHg respectively). 
Visual field changes
Numbers completing a reliable visual field exam decreased significantly year on year. Some attrition was due to the fact that a number of patients had 24-2
Humphrey visual fields pre-operation but only 10-2 fields post-operation. Postoperation there was no statistically significant deterioration in MD. Both the change in mean MD of the group as a whole and the change in individual patients' MDs for each of the time periods (years 1 (n=58),3 (n=29) and 5 (n=14)) remained stable with no statistically significant decline evident.
Visual acuity changes
Pre-operative acuities ranged from 6/6 to perception of light, with a median acuity of 6/12. Post-operative median acuity remained unchanged with a range of 6/6 to no perception of light. 28 patients experienced a significant reduction in acuity defined as 2 or more lines of Snellen. However, it should be noted only a minority of these were due to the surgery itself (table 3) .
No form of intervention was found to be associated with a significant reduction in acuity. The only pre-operative determinant for a significant reduction in VA was the pre-operative MD (-27.00dB (n=21) compared with -24.79dB (n=63))
indicating those patients with more advanced field defects were more likely to experience a reduction in VA post-operatively (p=0.029 Table 3 . Reasons for decline in VA.
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Cataract Surgery
The 
Bleb Manipulations
In total 83 (79.8%) patients had some form of bleb manipulation, the majority of which had an episode of bleb massage (64%), Final IOP success was otherwise not related to any form of intervention.
Discussion
For patients with advanced glaucoma target IOP is likely to be very low, introducing an additional challenge in this group of patients. Surgery has several potential advantages over medical management, including the magnitude of mean diurnal IOP lowering and the extent of any diurnal spiking of IOP. [12] Currently there are no reports of medium to long-term outcomes following MMC trabeculectomy in patients with advanced glaucoma. In this group of patients most likely to go blind from progressive disease such information would greatly inform management.
Intra-ocular pressure control
In our cohort IOP reduction was maintained significantly below pre-operation levels up to 6 years after surgery. Two previous studies have demonstrated adequate short-term IOP control between 3-12 months post-trabeculectomy with MMC in patients with advanced disease (MD -24.8 +/-4.1dB and -27.94 +/-2.7 respectively). [13, 14] in outcomes between consultants and trainees for this surgery, although more interventions were required to achieve this in the fellow group. This may reflect that although glaucoma fellows undergo extensive surgical exposure they are still surgeons in training and therefore require some additional interventions to achieve similar results.
The influence of cataract surgery on the outcomes of glaucoma surgery remains unresolved. [16] [17] [18] In our cohort, sub-group analysis indicated that cataract surgery following trabeculectomy had no effect on survival.
Change in visual field
Our study failed to demonstrate a decline in visual field over a time period 
Bleb manipulations
A high proportion of our patients (79.6%) had some form of manipulation postoperatively. In our attempt to minimise the potential risks associated with high dose MMC we tended to err on the side of caution when applying MMC. As a consequence some patients on the lower MMC doses required additional intervention (bleb manipulation) to manage post-operative bleb scarring. Another contributory factor could be the need to achieve low target IOPs and consequent intensive bleb manipulation to achieve this. However, our intervention rates were similar to a previous study of mixed visual field loss subjects suggesting patients
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with more advanced disease are no more likely to have any intervention postoperatively compared to those with less advanced disease. [8] Topouzis' prospective study on eyes with advanced glaucoma undergoing trabeculectomy augmented with MMC had similarly high intervention rates with 9/21 patients (43%) undergoing a 5 FU injection and 10/21 (48%) requiring argon suturelysis during a 3 month follow-up period.
[13]
Loss of vision
Worries exist as to the possibility of severe loss of central vision or "extinction" described as the sudden reduction of visual acuity after filtration surgery in endstage glaucoma, with no apparent ocular pathology to account for this decline. [20] In total 27% (28/104) experienced a significant reduction in VA defined by a loss of 2 or more lines of Snellen acuity. Cataract formation was in the order of 63%
which is comparable to that of the AGIS study (78% risk) and could not, by itself explain the drop in acuity. [21] The only pre-operative factor found to be predictive for VA loss was more advanced visual field loss. Additionally we were unable to demonstrate any association between post-op intervention and VA loss. This is significant as this is one of the first studies specifically assessing the impact of post-operative bleb manipulation on final VA. Importantly all but one had ocular pathology which explained this loss of acuity with a minority associated with the surgery. In the case where acuity was lost inexplicably (presumed wipeout) the VA dropped from 6/18 to HM post-operation. Estimates of the risk of severe loss of central vision range from rare to 15.4% in patients with advanced preoperative field defects. [13, 14, 20, 22, 23] Only two have concentrated specifically on trabeculectomy augmented with MMC. [13, 14] The larger of these studies suggests severe loss of central vision following surgery to be in the order of 6%, however none of these were attributed to extinction and of the 7 eyes (out of a total of 117) experiencing loss of central vision, the decline was attributed to hypotony maculopathy (3), uncontrolled elevated IOP (2), posterior subcapsular lens opacities (1) and inflammatory reaction (1) . [14] Similarly Topouzis' study of 21 consecutive patients with end-stage glaucoma undergoing MMC augmented trabeculectomy found no unexplained loss of vision although follow-up was for only 3 months. [13] Five patients had no identifiable cause for visual acuity loss. It is presumed that fluctuation in Snellen acuity accounted for their loss although this assumption cannot be proven. The extent of the loss in all these cases were 2 Snellen lines only.
The information in this study may be extrapolated to managing patients initially presenting with advanced disease. A relatively large number of patients continue to present with advanced glaucoma, which tends to be associated with social deprivation in the UK. [24, 25] A recent systematic review suggested that evidence from several studies supported the use of primary surgery over primary medical treatment in patients presenting with advanced glaucoma. [26] This is further supported from the results of CIGTS which indicated that patients with severe disease at presentation had slower visual field loss when randomised to the surgery group. [27] Furthermore primary surgery would avoid the effects of long term antiglaucoma therapy which may affect the outcomes of glaucoma surgery. [28, 29] Limitations of this study include the loss of numbers, particularly those able to complete a reliable visual field test during the follow-up period and refraction at 
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